Fig. 5: Antigenic analysis of NAs from recent H1N1 and type B vaccine strains by NASPA. | npj Vaccines

Fig. 5: Antigenic analysis of NAs from recent H1N1 and type B vaccine strains by NASPA.

From: Influenza neuraminidase active site proximity assay for rapid profiling of inhibitory antibodies and antigenic drift

Fig. 5

a NASPA results for each TX100-treated H1N1 vaccine strain with ferret antisera raised against the indicated reassortant virus are shown. The H1N1 strains A/Brisbane/59/2007 (BR07), A/California/07/2009 (CA09), A/Michigan/45/2015 (MI15), A/Brisbane/02/2018 (BR18) and A/Victoria/2570/2019 (Vic19) were analyzed. b NASPA results for each TX100-treated type B vaccine strain with ferret antisera raised against the indicated wild type and reassortant virus are displayed. The B Yamagata lineage strain B/Phuket/3073/2013 (Phu13) and the B Victoria lineage strains B/Brisbane/60/2008 (BR08), B/Colorado/06/2017 (CO17), B/Washington/02/2019 (WA19) and B/Austria/1359417/2021 (Austria21) were tested. All analysis were performed in duplicate using NAi-MAb concentrations corresponding to the IC80 and are shown as the mean ± SD of the NA activities measured for 10 min after MUNANA addition. Gray regions indicate the mean (dashed line) ± 3 SDs (dotted line) of the control wells.

Back to article page